image: Axiom Space, WFIRM and ReMDO
to see After

1 credit

WINSTON-SALEM, NC, April 18, 2022 – Manufacturing regenerative medicine in space is the next frontier and will be possible thanks to a new three-way partnership between Axiom Space, which is building the world’s first commercial space station, the RegenMed Development Organization (ReMDO), the premier organization dedicated to advancing the scale and automation of regenerative medicine manufacturing, and the Wake Forest Institute of Regenerative Medicine (WFIRM), an international leader in translating scientific discoveries in clinical therapies.

ReMDO and Axiom Space today announced plans to leverage the translational regenerative medicine expertise of the WFIRM team and Axiom’s leadership in developing commercial space infrastructure to advance regenerative medicine biomanufacturing in space.

To facilitate work to accelerate the translation of regenerative medicine technologies, Axiom is establishing a presence in Winston-Salem by officially registering as a tenant of RemDO’s Innovation Accelerator, with access to its testbed . RemDO’s testbed and WFIRM provide a research-friendly environment for companies to develop their products and access unparalleled resources.

This partnership provides the opportunity to grow the commercial space economy and support commercial biomedical innovations and manufacturing for biomedical applications in low orbit on the Axiom space station which will operate 250 miles above Earth. Research on the space station will be freed from the constraints of gravity, offering great potential and benefits.

Axiom Space made international news earlier this month with its Axiom 1 (Ax-1) mission, the first private mission to the International Space Station (ISS) which launched from NASA’s Kennedy Space Center in Florida. Ax-1 is the first of several planned missions to the ISS and an important step towards Axiom’s goal of building its space station to serve as a global research and commercial hub. The Axiom station will initially be attached to the ISS and will separate from it before NASA decommissions the ISS at the end of this decade.

“This partnership paves the way for an entire commercial industry aboard the Axiom space station that will allow our scientific research teams to advance biomanufacturing to bring new treatments that cannot be developed on Earth and treatments for the conditions that affect the human body when exposed to the harsh environment of space travel,” said Anthony Atala, MD, director of WFIRM. “We can literally take the field of regenerative medicine to a whole new level. .”

The Innovation Accelerator is a key part of the regenerative medicine ecosystem called the Regenerative Medicine Hub (RegenMed Hub™) and is positioned as a national leader in regenerative medicine innovation. The RegenMed Hub™, based in the Innovation District, brings together and leverages the resources and talent available through the Wake Forest Enterprise – Atrium Health Wake Forest Baptist, School of Medicine, and University. A number of regenerative medicine start-ups and established companies are already operating in the RegenMed Hub™ and region, providing extensive resources for entrepreneurs and life science professionals.

“As a member of the Innovation Accelerator, Axiom Space brings exciting capabilities that don’t exist anywhere else in the world,” said Josh Hunsberger, PhD, Chief Technology Officer of ReMDO. “In addition to our original goal, we anticipate further opportunities will arise from this collaboration that will lead to breakthroughs in regenerative medicine.”

Christian Maender, director of manufacturing and space research at Axiom Space, agrees. “We are very pleased to establish this collaboration and look forward to working with this world-renowned team to build and grow the commercial space economy for biomedical applications in low Earth orbit,” he said. “Regenerative medicine has been identified as an important focus area for commercial space initiatives that have the potential to provide new hope for breakthrough treatments and align with our mission to improve life on Earth and foster possibilities beyond.”

Media contact for WFIRM: Bonnie Davis, [email protected]; 336-493-6184

Media contact for Axiom Space: [email protected]

About the Wake Forest Institute for Regenerative Medicine: The Wake Forest Institute for Regenerative Medicine is recognized as an international leader in translating scientific discoveries into clinical therapies, with many world firsts, including the development and implantation of the first modified organ in a patient. More than 400 people at the institute, the largest in the world, work on more than 40 different tissues and organs. A number of basic principles of tissue engineering and regenerative medicine were first developed at the institute. WFIRM researchers have successfully designed replacement tissues and organs in all four categories – flat structures, tubular tissues, hollow organs and solid organs – and 15 different applications of cell/tissue therapy technologies, such as skin, tissue Urethra, cartilage, bladders, muscles, kidneys, and vaginal organs have been used successfully in human patients. The institute, part of the Wake Forest School of Medicine, is located in the Innovation District in downtown Winston-Salem, North Carolina, and is driven by urgent patient needs. The institute is making a global difference in regenerative medicine through collaborations with more than 400 entities and institutions around the world, through its government, academic and industrial partnerships, its start-ups and through major initiatives in the technologies of advanced, such as tissue engineering, cell therapies. , diagnostics, drug discovery, biomanufacturing, nanotechnology, gene editing and 3D printing. More information can be found at www.wfirm.org

About the RegenMed Development Organization: The mission of the RegenMed Development Organization (ReMDO) is to accelerate the discovery and translation of regenerative medicine therapies. ReMDO is a 501(c)3 nonprofit organization that operates a clinical translation initiative that includes thought leaders, representatives from major US research centers, government officials, and businesses of all sizes. ReMDO conducts research to reduce the risks of technologies and accelerate the translation of regenerative medicine into clinical practice and the global market. ReMDO operates the world’s first and only professional organization dedicated solely to advancing the field of regenerative medicine, the Regenerative Medicine Manufacturing Society (RMMS) and the Regenerative Medicine Manufacturing Innovation Consortium (RegMIC), which operates a public-private partnership industrial and academic members. focused on scaling up technologies. More information can be found at http://remdo.org/

About Axiom Space: Axiom Space is driven by the vision of a thriving home in space that benefits every human being, everywhere. The leading provider of human spaceflight services and developer of human-classified space infrastructure, Axiom today operates end-to-end missions to the International Space Station while privately developing its successor – a permanent commercial destination in orbit. earth that will support human growth off the planet and bring untold benefits back home. For more information about Axiom, visit www.axiomspace.com.


Warning: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.


Source link